Cargando…

Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis

PURPOSE: Perioperative chemotherapy improves survival outcomes in locally advanced (LA) gastric cancer. MATERIALS AND METHODS: We retrospectively analyzed patients with LA gastric cancer who were offered perioperative chemotherapy consisting of epirubicin, oxaliplatin, and capecitabine (EOX) from Ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ostwal, Vikas, Sahu, Arvind, Ramaswamy, Anant, Sirohi, Bhawna, Bose, Subhadeep, Talreja, Vikas, Goel, Mahesh, Patkar, Shraddha, Desouza, Ashwin, Shrikhande, Shailesh V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Gastric Cancer Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362831/ https://www.ncbi.nlm.nih.gov/pubmed/28337360 http://dx.doi.org/10.5230/jgc.2017.17.e3

Ejemplares similares

Oxaliplatin-related neuropathy in Indian patients – no difference between generic and original molecules
por: Sirohi, Bhawna, et al.
Publicado: (2016)

Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers
por: Harris, Caleb, et al.
Publicado: (2019)

Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India
por: Kulkarni, Suyash, et al.
Publicado: (2017)

Down-staging following neoadjuvant chemo-radiotherapy for locally advanced rectal cancer: Does timing of surgery really matter?
por: Sirohi, Bhawna, et al.
Publicado: (2014)

Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
por: Ostwal, Vikas, et al.
Publicado: (2017)

Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre
por: Ostwal, Vikas, et al.
Publicado: (2018)

Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India
por: Bhargava, Prabhat G., et al.
Publicado: (2020)

Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center
por: Bose, Subhadeep, et al.
Publicado: (2017)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India
por: Patkar, Shraddha, et al.
Publicado: (2023)

Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India
por: Sahu, Arvind, et al.
Publicado: (2017)

Development of a New Tool to Assess the Quality of Life of Patients with Hand–Foot Syndrome Receiving Capecitabine-Based Therapy: A Pilot Study
por: Jagdish, Prathepa, et al.
Publicado: (2022)

Reproductive factors and gall-bladder cancer, and the effect of common genetic variants on these associations: a case–control study in India
por: Mhatre, Sharayu, et al.
Publicado: (2021)

Cystic lesions of the pancreas: Improved understanding, diagnostics and refined outcomes
por: Sirohi, Bhawna, et al.
Publicado: (2013)

A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol
por: Engineer, Reena, et al.
Publicado: (2019)

An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers
por: Bhargava, Prabhat, et al.
Publicado: (2022)

A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer
por: Bozkaya, Yakup, et al.
Publicado: (2018)

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)
por: Ostwal, Vikas, et al.
Publicado: (2022)

Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer
por: Schønnemann, K R, et al.
Publicado: (2008)

Treatment of Metastatic Colorectal Cancers in Resource-Constrained Low- and Middle-Income Countries (LMICS) Scenario—Outcomes, Practice Patterns, and Commentary on Treatment Costs
por: Ramaswamy, Anant, et al.
Publicado: (2022)

Clinical trials in India: At uncertain crossroads?
por: Sirohi, Bhawna, et al.
Publicado: (2014)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
por: Shetty, Omshree, et al.
Publicado: (2022)

Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
por: Feng, Yan-Ru, et al.
Publicado: (2016)

Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers
por: Ostwal, Vikas, et al.
Publicado: (2019)

Indian Council of Medical Research consensus document on hepatocellular carcinoma
por: Sirohi, Bhawna, et al.
Publicado: (2020)

Simultaneous resection of synchronous colorectal liver metastasis: Feasibility and development of a prediction model
por: Kazi, Mufaddal, et al.
Publicado: (2023)

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
por: Waddell, Tom, et al.
Publicado: (2013)

The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2020)

Long Term Complete Remission in Advanced Gastric Adenocarcinoma With Docetaxel, Oxaliplatin and Capecitabine Combination Regimen
por: Goel, Gaurav
Publicado: (2012)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report
por: Pande, Nikhil, et al.
Publicado: (2019)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Financial Impact of Complex Cancer Surgery in India: A Study of Pancreatic Cancer
por: Basavaiah, Guruchanna, et al.
Publicado: (2018)

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019)

Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience
por: Pai, Trupti, et al.
Publicado: (2017)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_40422hr1u6is5u7ieafln07vr4